甲基化分类器及辅助方法对中枢神经系统肿瘤诊断的影响
该研究对连续1258例以会诊为主的手术神经病理样本采用整合诊断方法,行DKFZ/Heidelberg CNS肿瘤分类器DNA甲基化谱分析及无监督分析,必要时加做辅助检测。结果显示高置信度分类器评分(>0.84)占66.4%,在其中46.7%的病例中影响了诊断,26.9%为实质性新诊断;289例仅描述性诊断病例中约一半(144例,49.8%)经甲基化高置信度评分得以明确。肿瘤纯度与分类器评分显著相关(P = 1.15e-11),去卷积可将低肿瘤纯度下匹配为对照/炎性脑组织的疑似GBM解析为GBM甲基化谱。
要点
- 高置信度甲基化评分(>0.84)在66.4%的会诊病例中获得。
- 高置信度评分病例中46.7%诊断受影响,26.9%为实质性新诊断。
- 低评分病例中41.6%可经辅助方法解决诊断不确定性。
核心结论
- 甲基化分类器及辅助方法可影响诊断困难CNS肿瘤的诊断,并可通过去卷积等方法应对低评分与低肿瘤纯度问题。
研究设计与样本
- 对2年期间以会诊为主获得的连续1258例手术神经病理样本采用整合诊断方法。
- 行DKFZ/Heidelberg CNS肿瘤分类器DNA甲基化谱分析与分类,并对甲基化数据进行无监督分析。
- 在相关情况下加做辅助检测。
主要发现
- 会诊病例中66.4%达到高置信度甲基化分类器评分(>0.84)。
- 高置信度评分病例中46.7%诊断受影响,其中26.9%为实质性新诊断。
- 289例仅带描述性诊断的病例中,甲基化以高置信度评分解决约一半(144例,49.8%)。
- 低评分病例中41.6%经额外方法解决诊断不确定性。
- 肿瘤纯度与分类器评分显著相关(P = 1.15e-11)。
关键数值与推荐
- 高置信度甲基化分类器评分界定为>0.84。
临床怎么用
- 对诊断困难的CNS肿瘤病例可将甲基化分类器作为辅助手段,并结合辅助检测与去卷积分析处理低评分及低肿瘤纯度情形。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate CNS tumor diagnosis can be challenging, and methylation profiling can serve as an adjunct to classify diagnostically difficult cases. METHODS: An integrated diagnostic approach was employed for a consecutive series of 1258 surgical neuropathology samples obtained primarily in a consultation practice over 2-year period. DNA methylation profiling and classification using the DKFZ/Heidelberg CNS tumor classifier was performed, as well as unsupervised analyses of methylation data. Ancillary testing, where relevant, was performed. RESULTS: Among the received cases in consultation, a high-confidence methylation classifier score (>0.84) was reached in 66.4% of cases. The classifier impacted the diagnosis in 46.7% of these high-confidence classifier score cases, including a substantially new diagnosis in 26.9% cases. Among the 289 cases received with only a descriptive diagnosis, methylation was able to resolve approximately half (144, 49.8%) with high-confidence scores. Additional methods were able to resolve diagnostic uncertainty in 41.6% of the low-score cases. Tumor purity was significantly associated with classifier score (P = 1.15e-11). Deconvolution demonstrated that suspected glioblastomas (GBMs) matching as control/inflammatory brain tissue could be resolved into GBM methylation profiles, which provided a proof-of-concept approach to resolve tumor classification in the setting of low tumor purity. CONCLUSIONS: This work assesses the impact of a methylation classifier and additional methods in a consultative practice by defining the proportions with concordant vs change in diagnosis in a set of diagnostically challenging CNS tumors. We address approaches to low-confidence scores and confounding issues of low tumor purity.
引用
- Wu Z, Abdullaev Z, Pratt D, et al. Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. Neuro Oncol. 2022. PMID: 34555175. doi:10.1093/neuonc/noab227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。